Germany-based biotech Tubulis today announced a second and final closing of its Series C round totaling 344 million euros ...

Japan’s largest drugmaker Takeda today announced earnings results for the first half of fiscal year 2025 (six months ended September 30, 2025) and updated its full-year outlook.

US pharma major Eli Lilly today announced its financial results for the third-quarter of 2025, exceeding expectations and ...

Myrio’s lead asset, PHOX2B PC-CAR T, is a chimeric antigen receptor T-cell therapy entering human trials for high-risk ...

Swiss pharma giant Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic ...

Bristol Myers Squibb (NYSE: BMY) reported third-quarter 2025 revenue of $12.2 billion, up 3% year-on-year, with non-GAAP earnings per share of $1.63. Growth was driven by the company’s newer products, ...

Danish pharma major Novo Nordisk today confirmed that it submitted an unsolicited proposal to acquire Metsera, aiming to ...

Swiss drug developer Oculis Holding today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary ...

Austrian biotech VALANX Biotech has appointed Klaus Orlinger as chief scientific officer, reinforcing its leadership as the ...

Swiss generics and biosimilars drugmaker Sandoz today presented its net-sales performance for the nine months and third ...

South Korea-based Samsung Life Science Fund, created jointly between Samsung Biologics, Samsung Bioepis, and Samsung C&T , ...

US biotech Biogen (Nasdaq: BIIB) reported third-quarter 2025 revenue of $2.5 billion, up 3%, with GAAP diluted EPS of $3.17, ...